Anaclim Management Team

Dr. Alfonso J. Alanis

Dr. Alfonso J. Alanis, is a majority founding partner, Chief Executive Officer and Chairman of the Board of Anaclim LLC where he is responsible for the overall strategy and performance of the company.

Prior to working at Anaclim, Dr. Alanis was an Executive at Eli Lilly and Company where he served in different functions for 21 years, including seven years as the Chief Medical Officer and Vice President of Global Clinical Research for that company.

A U.S. citizen, Dr. Alanis was born in Mexico City where he attended Medical School, graduating Magna cum Laude from the National Autonomous University of Mexico (UNAM). He obtained his Internal Medicine, Infectious Disease and Clinical Microbiology training at the Cleveland Clinic in Cleveland, Ohio.

Dr. Alanis has been the recipient of different academic and research awards and honors, and a number of licenses and certifications and has authored several scientific publications and chapters in peer-reviewed medical journals and medical books. He is an active member of numerous professional societies.

Dr. Alanis lives in Zionsville, Indiana with his wife Maria del Carmen and his four sons.


Simone Guillot

Ms. Guillot is Director, Financial Operations of Anaclim with overall responsibility for financial management of the business including budgeting, planning, treasury functions, accounting and financial analysis.

Ms. Guillot is a CPA and CMA with over 10 years experience in various financial/ accounting departments within Fortune 500 companies. She spent two of those years at Eli Lilly & Co. supervising the Clinical Grants office which included all investigator and CRO payment transactions.

Ms. Guillot holds a B.S. in Accounting from Louisiana State University.

Mission Statement

To conduct minority focused clinical trials that produce high quality clinical information on time every time for pharmaceutical, biotechnology, CROs and other research organizations.

Vision Statement

Anaclim will be recognized throughout the industry as the premier CRO for conducting minority focused clinical trials that produce high quality and timely clinical information.